SOURCE: Advanced Proteome Therapeutics Corporation

Advanced Proteome Therapeutics Corporation

December 04, 2015 19:43 ET

Advanced Proteome Therapeutics Updates Study of APC 101

VANCOUVER, BC--(Marketwired - December 04, 2015) - Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE: APC) (FRANKFURT: 0E8) is following up on its news release of April 29, 2015 that reported on testing of APC 101 in the 4T1 mouse model.

The Company's technology is based on a proprietary protein modification platform that enables the attachment of entities to novel variants of the human protein annexin V in order to enhance its properties and/or endow it with additional functions, and then deliver them selectively to cancer cells. This type of agent, in the form of an annexin-drug conjugate, carrying a cytotoxic drug, is intended to directly attack and destroy cancer cells. A second strategy, independent of cytotoxic drugs, employs annexin modifications as immunomodulators, intended to stimulate an immune response that can be exploited to obtain durable responses.

Indeed, annexin V itself has been reported to be capable of conferring anti-tumor immunity in connection with its affinity for the biomarker phosphatidylserine (PS) exposed on cancer cells, but its activity is limited by a very short lifetime. In addition, there are clear precedents for molecules targeting PS exposed on tumor cells that have advanced in the clinic, establishing PS as a current therapeutic target.

In connection with an investigation of the immunomodulatory activity of one of APC's annexin V modifications, the Company's academic collaborators provided data from several experiments, indicating that APC 101 suppressed metastasis in the 4T1 model of breast cancer, which the company reported in a news release of April 29, 2015. Their observations were based on the effect of a single injection of APC 101, the most easily prepared of several chemically modified annexins the Company has developed, which was tested in the 4T1 mouse model, an aggressive tumor model that spontaneously metastasizes. The ability of just one treatment of a protein drug to suppress metastasis over several weeks in this model was unusual and lacked precedents, thus, as announced at the Company's Annual General Meeting held in July 2015, the Company sought confirmation of the results from an independent contract research organization (CRO).

The CRO has concluded their study and the results they obtained with APC 101 were not in accord with those of the academic collaborators in that a single injection of APC 101 during the course of the CRO study, was not adequate to suppress metastasis in the 4T1 mouse model. The reasons for the discrepancies are not clear and require access to additional information and further analysis to determine whether these two independent studies can be reconciled, which is currently being pursued.

About APC

APC has been applying its proprietary technologies to proteins targeted for the treatment of cancers. Advanced targeted therapies are designed to attack primarily cancer cells and are expected to dominate the anti-cancer therapeutics' market in the near future. The Company's goals are not only to employ therapy targeted for tumor cells, but to deliver therapy in the form of a single, pure therapeutic agent.

To achieve this end, it has been the Company's intention to utilize a unique protein (and related systems), not only as a delivery vehicle to tumor cells, but also as a scaffold upon which to attach each anti-cancer entity to its own specific site on the protein surface -- both key to efficient manufacturing and product development. The protein vehicle has emerged as a potential immunotherapeutic as it is implicated in activating the immune system to attack and help clear tumor cells. Immunotherapy is perhaps the most powerful current approach to cancer, and one of great commercial interest to the pharmaceutical industry.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. The forward-looking statements contained in this news release involve risks and uncertainties, and are subject to change based on various important factors including timely development and acceptance of new products, gaining product approval, successful entry into new markets, changes in financing conditions, and changes in FDA regulations.

Contact Information


    Advanced Proteome Therapeutics Corporation
    Alexander (Allen) Krantz
    President and Chief Executive Officer
    Tel: (617) 638-0340

    Scott Young
    Investor Relations
    Tel: (705) 888-2756